Literature DB >> 28520969

Cell-Mediated Immunity to Target the Persistent Human Immunodeficiency Virus Reservoir.

James L Riley1, Luis J Montaner2.   

Abstract

Effective clearance of virally infected cells requires the sequential activity of innate and adaptive immunity effectors. In human immunodeficiency virus (HIV) infection, naturally induced cell-mediated immune responses rarely eradicate infection. However, optimized immune responses could potentially be leveraged in HIV cure efforts if epitope escape and lack of sustained effector memory responses were to be addressed. Here we review leading HIV cure strategies that harness cell-mediated control against HIV in stably suppressed antiretroviral-treated subjects. We focus on strategies that may maximize target recognition and eradication by the sequential activation of a reconstituted immune system, together with delivery of optimal T-cell responses that can eliminate the reservoir and serve as means to maintain control of HIV spread in the absence of antiretroviral therapy (ART). As evidenced by the evolution of ART, we argue that a combination of immune-based strategies will be a superior path to cell-mediated HIV control and eradication. Available data from several human pilot trials already identify target strategies that may maximize antiviral pressure by joining innate and engineered T cell responses toward testing for sustained HIV remission and/or cure.
© The Author 2017. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  CAR; CCR5; Gene therapy; IFN-α.; NK

Mesh:

Year:  2017        PMID: 28520969      PMCID: PMC5853458          DOI: 10.1093/infdis/jix002

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  132 in total

1.  Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells.

Authors:  C Yee; J A Thompson; D Byrd; S R Riddell; P Roche; E Celis; P D Greenberg
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-11       Impact factor: 11.205

2.  Antigen-specific CD4 T-cell help rescues exhausted CD8 T cells during chronic viral infection.

Authors:  Rachael D Aubert; Alice O Kamphorst; Surojit Sarkar; Vaiva Vezys; Sang-Jun Ha; Daniel L Barber; Lilin Ye; Arlene H Sharpe; Gordon J Freeman; Rafi Ahmed
Journal:  Proc Natl Acad Sci U S A       Date:  2011-12-12       Impact factor: 11.205

Review 3.  Interferon signalling network in innate defence.

Authors:  Akinori Takaoka; Hideyuki Yanai
Journal:  Cell Microbiol       Date:  2006-06       Impact factor: 3.715

4.  Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity.

Authors:  John W Shiver; Tong-Ming Fu; Ling Chen; Danilo R Casimiro; Mary-Ellen Davies; Robert K Evans; Zhi-Qiang Zhang; Adam J Simon; Wendy L Trigona; Sheri A Dubey; Lingyi Huang; Virginia A Harris; Romnie S Long; Xiaoping Liang; Larry Handt; William A Schleif; Lan Zhu; Daniel C Freed; Natasha V Persaud; Liming Guan; Kara S Punt; Aimin Tang; Minchun Chen; Keith A Wilson; Kelly B Collins; Gwendolyn J Heidecker; V Rose Fernandez; Helen C Perry; Joseph G Joyce; Karen M Grimm; James C Cook; Paul M Keller; Denise S Kresock; Henryk Mach; Robert D Troutman; Lynne A Isopi; Donna M Williams; Zheng Xu; Kathryn E Bohannon; David B Volkin; David C Montefiori; Ayako Miura; Georgia R Krivulka; Michelle A Lifton; Marcelo J Kuroda; Jörn E Schmitz; Norman L Letvin; Michael J Caulfield; Andrew J Bett; Rima Youil; David C Kaslow; Emilio A Emini
Journal:  Nature       Date:  2002-01-17       Impact factor: 49.962

Review 5.  Increased intensity lymphodepletion and adoptive immunotherapy--how far can we go?

Authors:  Pawel Muranski; Andrea Boni; Claudia Wrzesinski; Deborah E Citrin; Steven A Rosenberg; Richard Childs; Nicholas P Restifo
Journal:  Nat Clin Pract Oncol       Date:  2006-12

6.  Massive ex vivo expansion of human natural regulatory T cells (T(regs)) with minimal loss of in vivo functional activity.

Authors:  Keli L Hippen; Sarah C Merkel; Dawn K Schirm; Christine M Sieben; Darin Sumstad; Diane M Kadidlo; David H McKenna; Jonathan S Bromberg; Bruce L Levine; James L Riley; Carl H June; Phillip Scheinberg; Daniel C Douek; Jeffrey S Miller; John E Wagner; Bruce R Blazar
Journal:  Sci Transl Med       Date:  2011-05-18       Impact factor: 17.956

7.  Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma.

Authors:  Adil I Daud; Kimberly Loo; Mariela L Pauli; Robert Sanchez-Rodriguez; Priscila Munoz Sandoval; Keyon Taravati; Katy Tsai; Adi Nosrati; Lorenzo Nardo; Michael D Alvarado; Alain P Algazi; Miguel H Pampaloni; Iryna V Lobach; Jimmy Hwang; Robert H Pierce; Iris K Gratz; Matthew F Krummel; Michael D Rosenblum
Journal:  J Clin Invest       Date:  2016-08-15       Impact factor: 14.808

8.  Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV.

Authors:  Pablo Tebas; David Stein; Winson W Tang; Ian Frank; Shelley Q Wang; Gary Lee; S Kaye Spratt; Richard T Surosky; Martin A Giedlin; Geoff Nichol; Michael C Holmes; Philip D Gregory; Dale G Ando; Michael Kalos; Ronald G Collman; Gwendolyn Binder-Scholl; Gabriela Plesa; Wei-Ting Hwang; Bruce L Levine; Carl H June
Journal:  N Engl J Med       Date:  2014-03-06       Impact factor: 91.245

9.  Lentiviral vectors encoding human immunodeficiency virus type 1 (HIV-1)-specific T-cell receptor genes efficiently convert peripheral blood CD8 T lymphocytes into cytotoxic T lymphocytes with potent in vitro and in vivo HIV-1-specific inhibitory activity.

Authors:  Aviva Joseph; Jian Hua Zheng; Antonia Follenzi; Teresa Dilorenzo; Kaori Sango; Jaime Hyman; Ken Chen; Alicja Piechocka-Trocha; Christian Brander; Erik Hooijberg; Dario A Vignali; Bruce D Walker; Harris Goldstein
Journal:  J Virol       Date:  2008-01-09       Impact factor: 5.103

10.  Increasing the potency and breadth of an HIV antibody by using structure-based rational design.

Authors:  Ron Diskin; Johannes F Scheid; Paola M Marcovecchio; Anthony P West; Florian Klein; Han Gao; Priyanthi N P Gnanapragasam; Alexander Abadir; Michael S Seaman; Michel C Nussenzweig; Pamela J Bjorkman
Journal:  Science       Date:  2011-10-27       Impact factor: 47.728

View more
  15 in total

1.  Interferon Alpha Enhances NK Cell Function and the Suppressive Capacity of HIV-Specific CD8+ T Cells.

Authors:  Abena K R Kwaa; Chloe A G Talana; Joel N Blankson
Journal:  J Virol       Date:  2019-01-17       Impact factor: 5.103

2.  Evaluation of the Innate Immune Modulator Acitretin as a Strategy To Clear the HIV Reservoir.

Authors:  Edurne Garcia-Vidal; Marc Castellví; Maria Pujantell; Roger Badia; Antoni Jou; Lucia Gomez; Teresa Puig; Bonaventura Clotet; Ester Ballana; Eva Riveira-Muñoz; José A Esté
Journal:  Antimicrob Agents Chemother       Date:  2017-10-24       Impact factor: 5.191

Review 3.  Clearance of HIV-1 or SIV reservoirs by promotion of apoptosis and inhibition of autophagy: Targeting intracellular molecules in cure-directed strategies.

Authors:  Min Chen; Min Li; Marietta M Budai; Andrew P Rice; Jason T Kimata; Mahesh Mohan; Jin Wang
Journal:  J Leukoc Biol       Date:  2022-03-31       Impact factor: 6.011

Review 4.  CAR T cells for infection, autoimmunity and allotransplantation.

Authors:  Colby R Maldini; Gavin I Ellis; James L Riley
Journal:  Nat Rev Immunol       Date:  2018-10       Impact factor: 53.106

5.  HIV-Specific, Ex Vivo Expanded T Cell Therapy: Feasibility, Safety, and Efficacy in ART-Suppressed HIV-Infected Individuals.

Authors:  Julia A Sung; Shabnum Patel; Matthew L Clohosey; Lauren Roesch; Tamara Tripic; JoAnn D Kuruc; Nancie Archin; Patrick J Hanley; C Russell Cruz; Nilu Goonetilleke; Joseph J Eron; Clio M Rooney; Cynthia L Gay; Catherine M Bollard; David M Margolis
Journal:  Mol Ther       Date:  2018-09-21       Impact factor: 11.454

6.  Broad-Spectrum and Personalized Guide RNAs for CRISPR/Cas9 HIV-1 Therapeutics.

Authors:  Will Dampier; Neil T Sullivan; Joshua Chang Mell; Vanessa Pirrone; Garth D Ehrlich; Cheng-Han Chung; Alexander G Allen; Mathew DeSimone; Wen Zhong; Katherine Kercher; Shendra Passic; Jean W Williams; Zsofia Szep; Kamel Khalili; Jeffrey M Jacobson; Michael R Nonnemacher; Brian Wigdahl
Journal:  AIDS Res Hum Retroviruses       Date:  2018-08-27       Impact factor: 2.205

7.  CCR5-edited CD4+ T cells augment HIV-specific immunity to enable post-rebound control of HIV replication.

Authors:  Pablo Tebas; Julie K Jadlowsky; Pamela A Shaw; Lifeng Tian; Erin Esparza; Andrea L Brennan; Sukyung Kim; Soe Yu Naing; Max W Richardson; Ashley N Vogel; Colby R Maldini; Hong Kong; Xiaojun Liu; Simon F Lacey; Anya M Bauer; Felicity Mampe; Lee P Richman; Gary Lee; Dale Ando; Bruce L Levine; David L Porter; Yangbing Zhao; Don L Siegel; Katharine J Bar; Carl H June; James L Riley
Journal:  J Clin Invest       Date:  2021-04-01       Impact factor: 19.456

Review 8.  Harnessing CD8+ T Cells Under HIV Antiretroviral Therapy.

Authors:  Joanna A Warren; Genevieve Clutton; Nilu Goonetilleke
Journal:  Front Immunol       Date:  2019-02-26       Impact factor: 7.561

9.  Simian Immunodeficiency Virus (SIV)-Specific Chimeric Antigen Receptor-T Cells Engineered to Target B Cell Follicles and Suppress SIV Replication.

Authors:  Kumudhini Preethi Haran; Agnes Hajduczki; Mary S Pampusch; Gwantwa Mwakalundwa; Diego A Vargas-Inchaustegui; Eva G Rakasz; Elizabeth Connick; Edward A Berger; Pamela J Skinner
Journal:  Front Immunol       Date:  2018-03-20       Impact factor: 7.561

10.  CD32 expression is associated to T-cell activation and is not a marker of the HIV-1 reservoir.

Authors:  Roger Badia; Ester Ballana; Marc Castellví; Edurne García-Vidal; Maria Pujantell; Bonaventura Clotet; Julia G Prado; Jordi Puig; Miguel A Martínez; Eva Riveira-Muñoz; José A Esté
Journal:  Nat Commun       Date:  2018-07-16       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.